Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
3.770
-0.400 (-9.59%)
At close: Nov 3, 2025, 4:00 PM EST
3.880
+0.110 (2.92%)
After-hours: Nov 3, 2025, 4:09 PM EST
Artiva Biotherapeutics Employees
Artiva Biotherapeutics had 89 employees as of December 31, 2024. The number of employees increased by 46 or 106.98% compared to the previous year.
Employees
89
Change
46
Growth
106.98%
Revenue / Employee
n/a
Profits / Employee
-$844,180
Market Cap
91.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89 | 46 | 106.98% |
| Dec 31, 2021 | 43 | 21 | 95.45% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARTV News
- 4 days ago - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 18 days ago - Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewsWire